A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501363-40-00

Acronym

NAV-1003

Enrollment

Registered

2023-01-12

Start date

2023-03-17

Completion date

2024-04-09

Last updated

2024-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS-G12C mutation and who are KRAS-G12Ci naïve, Advanced or metastatic solid tumors with a KRAS-G12C mutation

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, Denmark, France, Greece, Italy, Netherlands, Spain

Outcome results